Drug Profile
Research Programme: monoclonal antibody therapeutics - Eisai Inc/Wistar Institute
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Morphotek; Wistar Institute
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jul 2007 Preclinical development is ongoing
- 17 Apr 2007 Eisai acquires Morphotek
- 06 Feb 2002 Preclinical trials in Cancer in USA (Parenteral)